Полиморфизм онкогена LMP1 вируса Эпштейна–Барр в двух этнических группах россии, татар и славян, и его влияние на развитие некоторых злокачественных опухолей
Аннотация
Об авторах
В. Э. ГурцевичРоссия
Гурцевич Владимир Эдуардович – д.м.н., профессор, ведущий научный сотрудник лаборатории вирусного канцерогенеза
115478, Москва, Каширское ш., 24
Тел.: 8 910 444-83-52 (моб.)
К. В. Смирнова
Россия
к.б.н., руководитель лаборатории вирусного канцерогенеза ФГБУ Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина МЗ РФ; доцент кафедры биохимии и молекулярной биологии Национального медицинского университета им. Пирогова МЗ РФ
Москва
И. В. Ботезату
Россия
к.б.н., научный сотрудник группы биохимии опухолей
Москва
Т. Е. Душенькина
Россия
лаборант-исследователь лаборатории вирусного канцерогенеза
Москва
А. К. Лубенская
Россия
лаборант-исследователь лаборатории вирусного канцерогенеза
Москва
Э. Дубар
Россия
лаборант-исследователь лаборатории вирусного канцерогенеза
Москва
Н. Б. Сенюта
Россия
к.м.н., ведущий научный сотрудник лаборатории вирусного канцерогенеза
Москва
А. В. Лихтенштейн
Россия
д.б.н., ведущий научный сотрудник группы биохимии опухолей
Москва
С. В. Петров
Россия
д.м.н., профессор, руководитель лаборатории иммуногистохимической диагностики опухолей
г. Казань
Список литературы
1. Кривошеев Ю.В. Русь и монголы: исследование по истории Северо-Восточной Руси XII—XV вв. СПб.: Академия исследования культуры, 2015. 452 с.
2. Состояние онкологической помощи населению России в 2017 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Москва: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. 236 c.
3. Хрусталев Д.Г. Русь и монгольское нашествие (20–50 гг. XIII в.). СПб.: Евразия, 2015. 416 с.
4. Alexander F.E., Jarrett R.F., Lawrence D., Armstrong A.A., Freeland J., Gokhale D.A., Kane E., Taylor G.M., Wright D.H., Cartwright R.A. Risk factors for Hodgkin’s disease by Epstein–Barr virus (EBV) status: prior infection by EBV and other agents. Br. J. Cancer, 2000, vol. 82, pp. 1117–1121. doi: 10.1054/bjoc.1999.1049
5. Andreone P., Gramenzi A., Lorenzini S., Biselli M., Cursaro C., Pileri S., Bernardi M. Posttransplantation lymphoproliferative disorders. Arch. Intern. Med., 2003, vol. 163, pp. 1997–2004. doi: 10.1001/archinte.163.17.1997
6. Ayadi W., Khabir A., Hadhri-Guiga B., Fki L., Toumi N., Siala W., Charfi S., Fendri A., Makni H., Boudawara T., Ghorbel A., Gargouri A., Jlidi R., Gargouri R., Busson P., Drira M., Daoud J., Frikha M., Hammami A., Karray-Hakim H. North African and Southeast Asian nasopharyngeal carcinomas: between the resemblance and the dissemblance. Bull. Cancer, 2010, vol. 97, pp. 475–482. doi: 10.1684/bdc.2010.1090
7. Balfour H.H. Jr, Holman C.J., Hokanson K.M., Lelonek M.M., Giesbrecht J.E., White D.R., Schmeling D.O., Webb C.H., Cavert W., Wang D.H., Brundage R.C. A prospective clinical study of Epstein–Barr virus and host interactions during acute infectious mononucleosis. J. Infect. Dis., 2005, vol. 192, pp. 1505–1512. doi: 10.1086/491740
8. Blake S.M., Eliopoulos A.G., Dawson C.W., Young L.S. The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity. Virology, 2001, vol. 282, pp. 278–287. doi: 10.1006/viro.2001.0828
9. Botezatu I.V., Kondratova V.N., Shelepov V.P., Lichtenstein A.V. DNA melting analysis: application of the “open tube” format for detection of mutant KRAS. Anal. Biochem., 2011, vol. 419, pp. 302–308. doi: 10.1016/j.ab.2011.08.015
10. Cederberg L.E., Rabinovitch M.D., Grimm-Geris J.M., Schmeling D.O., Filtz E.A., Condon L.M., Balfour H.H.Jr. Epstein–Barr virus DNA in parental oral secretions: a potential source of infection for their young children. Clin. Infect. Dis., 2018. doi: 10.1093/cid/ciy464
11. Chang C.M., Yu K.J., Mbulaiteye S.M., Hildesheim A., Bhatia K. The extent of genetic diversity of Epstein–Barr virus and its geographic and disease patterns: a need for reappraisal. Virus Res., 2009, vol. 143, pp. 209–221. doi: 10.1016/j.virusres.2009.07.005
12. Dawson D.R., Wang C., Danaher R.J., Lin Y., Kryscio R.J., Jacob R.J., Miller C.S. Salivary levels of Epstein–Barr virus DNA correlate with subgingival levels, not severity of periodontitis. Oral Dis., 2009, vol. 15, pp. 554–559. doi: 10.1111/j.16010825.2009.01585.x
13. Dirmeier U., Neuhierl B., Kilger E., Reisbach G., Sandberg M.L., Hammerschmidt W. Latent membrane protein 1 is critical for efficient growth transformation of human B cells by epstein-barr virus. Cancer Res., 2003, vol. 63, pp. 2982–2989.
14. Dunmire S.K., Hogquist K.A., Balfour H.H. Infectious Mononucleosis. Curr. Top. Microbiol. Immunol., 2015, vol. 390, pp. 211–240. doi: 10.1038/cti.2015.1
15. Edwards R.H., Seillier-Moiseiwitsch F., Raab-Traub N. Signature amino acid changes in latent membrane protein 1 distinguish Epstein–Barr virus strains. Virology, 1999, vol. 261, pp. 79–95. doi: 10.1006/viro.1999.9855
16. Farrell P.J. Signal transduction from the Epstein–Barr virus LMP-1 transforming protein. Trends Microbiol., 1998, vol. 6, pp. 175–177.
17. Feederle R., Klinke O., Kutikhin A., Poirey R., Tsai M.H., Delecluse H.J. Epstein–Barr virus: from the detection of sequence polymorphisms to the recognition of viral types. Curr. Top. Microbiol. Immunol., 2015, vol. 390, pp. 119–148. doi: 10.1007/978-3319-22822-8_7
18. Gantuz M., Lorenzetti M.A., Chabay P.A., Preciado M.V. A novel recombinant variant of latent membrane protein 1 from Epstein Barr virus in Argentina denotes phylogeographical association. PLoS One, 2017, vol. 12: e0174221. doi: 10.1371/journal.pone.0174221
19. Gerber P., Walsh J.H., Rosenblum E.N., Purcell R.H. Association of EB-virus infection with the post-perfusion syndrome. Lancet, 1969, vol. 1, pp. 593–595.
20. Gurtsevitch V.E., Iakovleva L.S., Shcherbak L.N., Goncharova E.V., Smirnova K.V., Diduk S.V., Kondratova V.N., Maksimovich D.M., Lichtenstein A.V., Seniuta N.B. The LMP1 oncogene sequence variations in patients with oral tumours associated or not associated with the Epstein–Barr. Mol. Biol., 2013, vol. 47, pp. 987–995.
21. Hadinoto V., Shapiro M., Sun C.C., Thorley-Lawson D.A. The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog., 2009, vol. 5: e1000496. doi: 10.1371/journal.ppat.1000496
22. Hahn P., Novikova E., Scherback L., Janik C., Pavlish O., Arkhipov V., Nicholls J., Muller-Lantzsch N., Gurtsevitch V., Grasser F.A. The LMP1 gene isolated from Russian nasopharyngeal carcinoma has no 30-bp deletion. Int. J. Cancer., 2001, vol. 91, pp. 815–821.
23. Hu L., Troyanovsky B., Zhang X., Trivedi P., Ernberg I., Klein G. Differences in the immunogenicity of latent membrane protein 1 (LMP1) encoded by Epstein–Barr virus genomes derived from LMP1-positive and -negative nasopharyngeal carcinoma. Cancer Res., 2000, vol. 60, pp. 5589–5593.
24. Hu L.F., Chen F., Zheng X., Ernberg I., Cao S.L., Christensson B., Klein G., Winberg G. Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. Oncogene, 1993, vol. 8, pp. 1575–1583.
25. Huen D.S., Henderson S.A., Croom-Carter D., Rowe M. The Epstein–Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene, 1995, vol. 10, pp. 549–560.
26. Kanai K., Satoh Y., Saiki Y., Ohtani H., Sairenji T. Difference of Epstein–Barr virus isolates from Japanese patients and African Burkitt’s lymphoma cell lines based on the sequence of latent membrane protein 1. Virus Genes, 2007, vol. 34, pp. 55–61. doi: 10.1007/s11262-006-0010-y
27. Kaye K.M., Izumi K.M., Kieff E. Epstein–Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl Acad. Sci. USA, 1993, vol. 90, pp. 9150–9154.
28. Kulwichit W., Edwards R.H., Davenport E.M., Baskar J.F., Godfrey V., Raab-Traub N. Expression of the Epstein–Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc. Natl Acad. Sci. USA, 1998, vol. 95, pp. 11963–11968.
29. Laichalk L.L., Hochberg D., Babcock G.J., Freeman R.B., Thorley-Lawson D.A. The dispersal of mucosal memory B cells: evidence from persistent EBV infection. Immunity, 2002, vol. 16, pp. 745–754.
30. Lawrence J.B., Villnave C.A., Singer R.H. Sensitive, high-resolution chromatin and chromosome mapping in situ: presence and orientation of two closely integrated copies of EBV in a lymphoma line. Cell, 1988, vol. 52, pp. 51–61.
31. Li H.P., Chang Y.S. Epstein–Barr virus latent membrane protein 1: structure and functions. J. Biomed. Sci., 2003, vol. 10, pp. 490–504. doi: 10.1159/000072376
32. Lo Y.M., Chan L.Y., Lo K.W., Leung S.F., Zhang J., Chan A.T., Lee J.C., Hjelm N.M., Johnson P.J., Huang D.P. Quantitative analysis of cell-free Epstein–Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res., 1999, vol. 59, pp. 1188–1191.
33. Miller W.E., Edwards R.H., Walling D.M., Raab-Traub N. Sequence variation in the Epstein–Barr virus latent membrane protein 1. J. Gen. Virol., 1994, vol. 75 (pt. 10), pp. 2729–2740. doi: 10.1099/0022-1317-75-10-2729
34. Moorthy R.K., Thorley-Lawson D.A. All three domains of the Epstein–Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J. Virol., 1993, vol. 67, pp. 1638–1646.
35. Namikawa T., Fujisawa K., Munekage E., Munekage M., Oki Y., Maeda H., Kitagawa H., Ueta H., Kobayashi M., Hanazaki K. Epstein–Barr virus-associated early gastric carcinoma with lymphoid stroma, accompanied with lymph node metastasis. Mol. Clin. Oncol., 2018, vol. 8, pp. 561–566. doi: 10.3892/mco.2018.1567
36. Neves M., Marinho-Dias J., Ribeiro J., Sousa H. Epstein–Barr virus strains and variations: geographic or disease-specific variants? J. Med. Virol., 2017, vol. 89, pp. 373–387. doi: 10.1002/jmv.24633
37. Rickinson A.B., Long H.M., Palendira U., Munz C., Hislop A.D. Cellular immune controls over Epstein–Barr virus infection: new lessons from the clinic and the laboratory. Trends Immunol., 2014, vol. 35, pp. 159–169. doi: 10.1016/j.it.2014.01.003
38. Rickinson A.B., Moss D.J. Human cytotoxic T lymphocyte responses to Epstein–Barr virus infection. Annu. Rev. Immunol., 1997, vol. 15, pp. 405–431. doi: 10.1146/annurev.immunol.15.1.405
39. Saechan V., Settheetham-Ishida W., Kimura R., Tiwawech D., Mitarnun W., Ishida T. Epstein–Barr virus strains defined by the latent membrane protein 1 sequence characterize Thai ethnic groups. J. Gen. Virol., 2010, vol. 91, pp. 2054–2061. doi: 10.1099/vir.0.021105-0
40. Santpere G., Darre F., Blanco S., Alcami A., Villoslada P., Mar A.M., Navarro A. Genome-wide analysis of wild-type EpsteinBarr virus genomes derived from healthy individuals of the 1,000 Genomes Project. Genome Biol. Evol., 2014, vol. 6, pp. 846–860. doi: 10.1093/gbe/evu054
41. Senyuta N., Yakovleva L., Goncharova E., Scherback L., Diduk S., Smirnova K., Maksimovich D., Gurtsevitch V. Epstein–Barr virus latent membrane protein 1 polymorphism in nasopharyngeal carcinoma and other oral cavity tumors in Russia. J. Med. Virol., 2014, vol. 86, pp. 290–300. doi: 10.1002/jmv.23729
42. Tzellos S., Farrell P.J. Epstein–Barr virus sequence variation-biology and disease. Pathogens, 2012, vol. 1, pp. 156–174. doi: 10.3390/pathogens1020156
43. Weiss L.M., Gaffey M.J., Chen Y.Y., Frierson H.F.Jr. Frequency of Epstein–Barr viral DNA in “Western” sinonasal and Waldeyer’s ring non-Hodgkin’s lymphomas. Am. J. Surg. Pathol., 1992, vol. 16, pp. 156–162.
44. Wu L.Y., Cheng J., Lu Y., Zhou Z.Y., Saku T. Epstein–Barr virus infection in benign lymphoepithelial lesions with malignant transformation of salivary glands. Zhonghua Kou Qiang Yi Xue Za Zhi, 2004, vol. 39, pp. 291–293.
45. Young L.S., Rickinson A.B. Epstein–Barr virus: 40 years on. Nat. Rev. Cancer, 2004, vol. 4, pp. 757–768. doi: 10.1038/nrc1452
Дополнительные файлы
Для цитирования:
Гурцевич В.Э., Смирнова К.В., Ботезату И.В., Душенькина Т.Е., Лубенская А.К., Дубар Э., Сенюта Н.Б., Лихтенштейн А.В., Петров С.В. Полиморфизм онкогена LMP1 вируса Эпштейна–Барр в двух этнических группах россии, татар и славян, и его влияние на развитие некоторых злокачественных опухолей. Инфекция и иммунитет. 2020;10(2):347-358. https://doi.org/10.15789/2220-7619-EBV-1162
For citation:
Gurtsevitch V.E., Smirnova K.V., Botezatu I.V., Dushenkina T.E., Lubenskaya A.K., Dubar E., Senyuta N.B., Lichtenstein A.V., Petrov S.V. Epstein–Barr virus LMP1 oncogene polymorphism in tatar and slavic populations in Russian Federation impacting on some malignant tumours. Russian Journal of Infection and Immunity. 2020;10(2):347-358. https://doi.org/10.15789/2220-7619-EBV-1162